Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.090
-0.040 (-3.54%)
At close: Jan 9, 2026, 4:00 PM EST
1.070
-0.020 (-1.83%)
After-hours: Jan 9, 2026, 6:26 PM EST

Company Description

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Citius Oncology, Inc.
Citius Oncology logo
CountryUnited States
Founded2021
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
CEOLeonard Mazur

Contact Details

Address:
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
United States
Phone908 967 6677

Stock Details

Ticker SymbolCTOR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code1851484
CUSIP Number17331Y109
ISIN NumberUS17331Y1091
Employer ID99-4362660
SIC Code2834

Key Executives

NamePosition
Leonard L. MazurChief Executive Officer, President and Executive Chairman
Myron Z. HolubiakSecretary and Executive Vice Chairman
Dr. Myron S. Czuczman M.D.Executive Vice President and Chief Medical Officer
Jaime BartushakChief Financial Officer and Treasurer

Latest SEC Filings

DateTypeTitle
Jan 5, 2026S-3Registration statement under Securities Act of 1933
Dec 23, 20258-KCurrent Report
Dec 23, 202510-KAnnual Report
Dec 17, 2025SCHEDULE 13D/AFiling
Dec 10, 20258-KCurrent Report
Dec 10, 2025424B5Filing
Dec 1, 20258-KCurrent Report
Nov 14, 2025SCHEDULE 13GFiling
Oct 27, 20258-KCurrent Report
Oct 23, 20258-KCurrent Report